Table 1. Characteristics of recipients of tixagevimab-cilgavimab (T/C) who developed COVID-19 infection between December 19, 2021 and July 31, 2022 when Omicron was the dominant circulating variant.
Characteristics of T/C recipients who were infected prior to receiving T/C (pre-T/C) are compared with characteristics of T/C recipients who were diagnosed with COVID after having received any dose of T/C (post-T/C).
| Patient Characteristic | Patients with COVID-19 infection pre-T/C (n = 105) | Patients with COVID-19 infection post-T/C (n = 102) | p-value |
|---|---|---|---|
| Median age [range], years | 54.0 [18–79] | 60.5 [25–99] | p = 0.008 |
| Patient gender | N.S. | ||
| Male (%) | 58 (55.2) | 58 (56.9) | |
| Female (%) | 47 (44.8) | 44 (43.1) | |
| Underlying conditions | N.S. | ||
| Solid organ transplantation (%) | 43 (41.0) | 35 (34.3) | |
| Hematologic malignancy or bone marrow transplantation (%) | 46 (43.8) | 56 (54.9) | |
| Other (%)• | 16 (15.2) | 11 (10.8) | |
| Number (%) of vaccine doses received prior to COVID diagnosis † | p < 0.001 | ||
| 0 | 15 (14.3) | 3 (2.9) | |
| 1–2 | 29 (27.6) | 25 (24.8) | |
| 3 | 53 (50.5) | 36 (35.6) | |
| 4 | 8 (7.6) | 37 (36.6) | |
| Therapeutics received (%) * | p ≤ 0.001 | ||
| Nirmatrelvir-Ritonavir | 5 (4.8) | 40 (39.2) | |
| Bebtelovimab | 0 (0.0) | 34 (33.3) | |
| Remdesivir | 18* (17.1) | 17 (16.7) | |
| Sotrovimab | 57* (54.3) | 2 (2.0) | |
| None | 26 (24.8) | 9 (8.8) | |
| Number of patients hospitalized (%) | 26 (24.8) | 6 (5.9) | p < 0.001 |
| Number of ICU admissions (%) | 7 (6.7) | 0 (0.0) | p = 0.008 |
| Number of deaths from COVID-19 (%) | 0 (0.0) | 0 (0.0) | — |
•Including autoimmune conditions, HIV/AIDS, and solid tumor malignancy
†One patient’s vaccine history was not documented within the electronic medical record
*One patient was treated with both sotrovimab and remdesivir
Abbreviations:
ICU = Intensive Care Unit